Peter Nygren

ORCID: 0000-0003-0075-127X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal Cancer Treatments and Studies
  • Cancer Treatment and Pharmacology
  • Cancer therapeutics and mechanisms
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Gastric Cancer Management and Outcomes
  • Intraperitoneal and Appendiceal Malignancies
  • Cancer, Hypoxia, and Metabolism
  • Drug Transport and Resistance Mechanisms
  • Computational Drug Discovery Methods
  • Acute Lymphoblastic Leukemia research
  • Cancer Research and Treatments
  • Ovarian cancer diagnosis and treatment
  • Appendicitis Diagnosis and Management
  • Parathyroid Disorders and Treatments
  • Pancreatic and Hepatic Oncology Research
  • Peptidase Inhibition and Analysis
  • Lung Cancer Treatments and Mutations
  • Metabolism, Diabetes, and Cancer
  • Pharmacogenetics and Drug Metabolism
  • Cancer, Lipids, and Metabolism
  • Acute Myeloid Leukemia Research
  • Hernia repair and management
  • HER2/EGFR in Cancer Research
  • Cancer survivorship and care
  • 3D Printing in Biomedical Research

Uppsala University
2015-2024

Uppsala University Hospital
2009-2023

Ericsson (Sweden)
2022-2023

Science for Life Laboratory
2017-2020

Vanderbilt University
2004

Sophiahemmet Hospital
2004

Karolinska Institutet
2004

PharmacoGenetics (China)
2004

UiT The Arctic University of Norway
1999

Karolinska University Hospital
1998

Abstract Abnormal vascularization of solid tumours results in the development microenvironments deprived oxygen and nutrients that harbour slowly growing metabolically stressed cells. Such cells display enhanced resistance to standard chemotherapeutic agents repopulate after therapy. Here we identify small molecule VLX600 as a drug is preferentially active against quiescent colon cancer 3-D microtissues. The anticancer activity associated with reduced mitochondrial respiration, leading...

10.1038/ncomms4295 article EN cc-by Nature Communications 2014-02-18

Abstract An automated fluorometric microculture cytotoxicity assay (FMCA) based on the measurement of fluorescence generated from cellular hydrolysis fluorescein diacetate (FDA) to was employed for chemotherapeutic‐drug‐sensitivity testing tumor‐cell suspensions patients with leukemia. Fluorescence linearly related cell number, and reproducible measurements drug sensitivity could be performed using fresh or cryopreserved leukemia cells. A marked heterogeneity respect chemotherapeutic...

10.1002/ijc.2910500204 article EN International Journal of Cancer 1992-01-21

Abstract Because dormant cancer cells in hypoxic and nutrient-deprived regions of solid tumors provide a major obstacle to treatment, compounds targeting those might have clinical benefits. Here, we describe high-throughput drug screening approach, using glucose-deprived multicellular tumor spheroids (MCTS) with inner hypoxia, identify that specifically target this cell population. We used concept repositioning—using known molecules for new indications. This is promising strategy rapid...

10.1158/1535-7163.mct-14-0792 article EN Molecular Cancer Therapeutics 2015-04-25

In the present study, we screened a compound library containing 1,600 clinically used compounds with aim to identify compounds, which potentially could be repositioned for colon cancer therapy.Two established cell lines were tested using fluorometric microculture cytotoxicity assay (FMCA). For comparison connectivity map (CMAP) analysis, NCI 60 data mining and protein kinase binding measurements performed.Sixty-eight defined as hits activity in both of these (<40 % survival compared control)...

10.1007/s00432-013-1539-5 article EN cc-by Journal of Cancer Research and Clinical Oncology 2013-10-17

Exercise during cancer treatment improves cancer-related fatigue (CRF), but the importance of exercise intensity for CRF is unclear. We compared effects high- vs low-to-moderate-intensity with or without additional behavior change support (BCS) on in patients undergoing (neo-)adjuvant treatment. This was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials NCT02473003) Sweden. Participants recently diagnosed breast (n = 457), prostate 97) colorectal 23) were to...

10.1111/sms.13930 article EN cc-by-nc Scandinavian Journal of Medicine and Science in Sports 2021-02-03

Patients with peritoneal or local metastases from colorectal cancer have a poor prognosis. However, aggressive treatments by debulking surgery and infusional intraperitoneal (i.p.) chemotherapy been tried appear to benefit selected patients. We assayed the effects of i.p. respect survival compared results matched control patients treated intravenous (i.v.) chemotherapy. In all, 18 and/or adenocarcinoma underwent followed 5-fluorouracil (5-FU) 550 mg m−2 day−1 leucovorin (LV) 60 i.v. The was...

10.1038/sj.bjc.6601586 article EN cc-by-nc-sa British Journal of Cancer 2004-01-01

The proteasome pathway is an important target for anticancer drug development. Here, we identify the antialcoholism disulfiram and its analogue pyrrolidine dithiocarbamate (PDTC) as inhibitors of 26S activity in a cell-based screening assay. As expected inhibitors, these compounds also inhibited TNF-alpha-induced nuclear factor-KappaB (NF-KappaB) translocation were cytotoxic. Disulfiram was more cytotoxic against chronic lymphocytic leukemia cells compared to peripheral blood mononuclear...

10.1002/ijc.21534 article EN International Journal of Cancer 2005-10-04

Paclitaxel pharmacokinetics are nonlinear with saturable metabolism and distribution to the tissues. The has in previous pharmacokinetic modeling been described as a transport process, whereas present study was undertaken investigate alternative explanations. Using sparse sampling scheme (on average 3.3 samples per profile), 101 plasma concentration-time profiles 22 female patients metastatic cancer of breast or ovary were monitored. It found that observed data could be equally well by...

10.1016/s0090-9556(24)15049-0 article EN Drug Metabolism and Disposition 2018-05-01

Progress in cancer biomarker discovery is dependent on access to high-quality biological materials and high-resolution clinical data from the same cases. To overcome current limitations, a systematic prospective longitudinal sampling of multidisciplinary data, blood tissue patients was therefore initiated 2010 by Uppsala Umeå Universities involving their corresponding University Hospitals, which are referral centers for one third Swedish population.Patients with selected types who treated at...

10.1080/0284186x.2017.1337926 article EN cc-by-nc-nd Acta Oncologica 2017-06-20

Abstract Poorly vascularized areas of solid tumors contain quiescent cell populations that are resistant to cycle-active cancer drugs. The compound VLX600 was recently identified target tumor cells and inhibit mitochondrial respiration. We here performed gene expression analysis in order characterize the cellular response VLX600. compound-specific signature revealed a striking similarity signatures generated by compounds known chelate iron. Validation experiments including addition ferrous...

10.1038/srep38343 article EN cc-by Scientific Reports 2016-12-07
Coming Soon ...